Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Validation of the measure of ovarian symptoms and treatment concerns (MOST), a patient-reported outcome measure (PROM) of symptom burden and subjective benefit with chemotherapy in recurrent ovarian cancer (ROC) King, M., Stockler, M., O'Connell, R., Joly, F., Lanceley, A., Hilpert, F., Okamoto, A., Aotani, E., Pignata, S., Donnellan, P., Oza, A., Avall-Lundqvist, E., Berek, J., Buizen, L., Sjoquist, K., Gillies, K., Butow, P., Friedlander, M., GCIG Symptom Benefit Study Grp, Gynecologic Canc Intergrp GCIG SPRINGER. 2015: 22–23
View details for Web of Science ID 000361991100056